The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?
Abstract
A majority of the novel orally administered, molecularly targeted anticancer therapies are weak bases that exhibit pH-dependent solubility, and suppression of gastric acidity with acid-reducing agents could impair their absorption. In addition, a majority of cancer patients frequently take acid-reducing agents to alleviate symptoms of gastroesophageal reflux disease, thereby raising the potential for a common but underappreciated drug-drug interaction (DDI) that could decrease the exposure of anticancer medication and result in subsequent failure of therapy. This article is a review of the available clinical literature describing the extent of the interaction between 15 orally administered, small-molecule targeted anticancer therapies and acid-reducing agents. The currently available clinical data suggest that the magnitude of this DDI is largest for compounds whose in vitro solubility varies over the pH range 1-4. This range represents the normal physiological gastric acidity (pH ~1) and gastric acidity while on an acid-reducing agent (pH ~4).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Self-citationWu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401
Self-citationPredicting in vivo drug interactions from in vitro drug discovery data
Wienkers, L. C., & Heath, T. G. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1851 · Cited by 904
SIM, S., RISINGER, C., DAHL, M., AKLILLU, E., CHRISTENSEN, M., BERTILSSON, L., & INGELMANSUNDBERG, M. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.10.002 · Cited by 732
BDDCS Applied to Over 900 Drugs
Benet, L. Z., Broccatelli, F., & Oprea, T. I. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9290-9 · Cited by 626
Self-citationCustodio, J. M., Wu, C.-Y., & Benet, L. Z. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.043 · Cited by 434
Self-citationPharmacokinetic variability of anticancer agents
Undevia, S. D., Gomez-Abuin, G., & Ratain, M. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1629 · Cited by 258
Introduction to computational oral absorption simulation
Sugano, K. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902835506 · Cited by 132
Klotz, U. E. (2006) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp44297 · Cited by 132
Eley, T., Luo, F., Agrawal, S., Sanil, A. P., Manning, J., Li, T., Blackwood‐Chirchir, A., & Bertz, R. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009333854 · Cited by 109
Cited by
The quest to overcome resistance to EGFR-targeted therapies in cancer
Chong, C. R., & Jänne, P. A. (2013) · Nature Medicine · doi:10.1038/nm.3388 · Cited by 1,052
Understanding and targeting resistance mechanisms in NSCLC
Rotow, J., & Bivona, T. G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.84 · Cited by 972
Acquired resistance to TKIs in solid tumours: learning from lung cancer
Camidge, D. R., Pao, W., & Sequist, L. V. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.104 · Cited by 862
Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
Westover, D., Zugazagoitia, J., Cho, B. C., Lovly, C. M., & Paz-Ares, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx703 · Cited by 766
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Tsume, Y., Mudie, D. M., Langguth, P., Amidon, G. E., & Amidon, G. L. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.01.009 · Cited by 350
PBPK models for the prediction of in vivo performance of oral dosage forms
Kostewicz, E. S., Aarons, L., Bergstrand, M., Bolger, M. B., Galetin, A., Hatley, O., Jamei, M., Lloyd, R., Pepin, X., Rostami-Hodjegan, A., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.09.008 · Cited by 315
Yang, Y., Li, S., Wang, Y., Zhao, Y., & Li, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01168-8 · Cited by 294
Sjögren, E., Abrahamsson, B., Augustijns, P., Becker, D., Bolger, M. B., Brewster, M., Brouwers, J., Flanagan, T., Harwood, M., Heinen, C., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.010 · Cited by 279
Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective
van Leeuwen, R. W. F., van Gelder, T., Mathijssen, R. H. J., & Jansman, F. G. A. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70579-5 · Cited by 279
Peters, S., Zimmermann, S., & Adjei, A. A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.06.010 · Cited by 155
Lin, W., Chen, Y., Unadkat, J. D., Zhang, X., Wu, D., & Heimbach, T. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03274-2 · Cited by 137
Parrott, N. J., Yu, L. J., Takano, R., Nakamura, M., & Morcos, P. N. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9957-3 · Cited by 77
Metadata
- Authors
- Budha, N. R., Frymoyer, A., Smelick, G. S., Jin, J. Y., Yago, M. R., Dresser, M. J., Holden, S. N., Benet, L. Z., & Ware, J. A.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2012-06-27
- Volume
- 92
- Issue
- 2
- Pages
- 203-213
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2143555751
- Cited by
- 338
- References
- 24
- FWCI
- 18.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.